- Home
- OFS vs TLSA Comparison
OFS vs TLSA Comparison
Compare OFS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- TLSA
- Stock Information
- Founded
- OFS 2001
- TLSA 2013
- Country
- OFS United States
- TLSA United Kingdom
- Employees
- OFS N/A
- TLSA N/A
- Industry
- OFS Finance/Investors Services
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- OFS Finance
- TLSA Health Care
- Exchange
- OFS Nasdaq
- TLSA Nasdaq
- Market Cap
- OFS 108.5M
- TLSA 87.8M
- IPO Year
- OFS 2012
- TLSA 2000
- Fundamental
- Price
- OFS $8.25
- TLSA $0.82
- Analyst Decision
- OFS
- TLSA
- Analyst Count
- OFS 0
- TLSA 0
- Target Price
- OFS N/A
- TLSA N/A
- AVG Volume (30 Days)
- OFS 29.5K
- TLSA 396.2K
- Earning Date
- OFS 03-07-2025
- TLSA 03-04-2025
- Dividend Yield
- OFS 16.48%
- TLSA N/A
- EPS Growth
- OFS N/A
- TLSA N/A
- EPS
- OFS N/A
- TLSA N/A
- Revenue
- OFS $49,799,000.00
- TLSA N/A
- Revenue This Year
- OFS N/A
- TLSA N/A
- Revenue Next Year
- OFS N/A
- TLSA N/A
- P/E Ratio
- OFS N/A
- TLSA N/A
- Revenue Growth
- OFS N/A
- TLSA N/A
- 52 Week Low
- OFS $7.75
- TLSA $0.41
- 52 Week High
- OFS $11.94
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- OFS 53.92
- TLSA 54.65
- Support Level
- OFS $8.02
- TLSA $0.65
- Resistance Level
- OFS $8.49
- TLSA $0.94
- Average True Range (ATR)
- OFS 0.13
- TLSA 0.06
- MACD
- OFS 0.03
- TLSA 0.02
- Stochastic Oscillator
- OFS 48.94
- TLSA 61.26
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.